Generics eroding the strength of the core portfolio
19/08/19 -"Lundbeck reported a mixed set of numbers in Q2. While the revenue decline of 10% (at CER) was lower than the street’s expectations, higher SG&A conspired to reduce the net margin by 2.7ppt ..."
Pages
51
Language
English
Published on
19/08/19
You may also be interested by these reports :
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...
23/04/24
The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...